Wysowski D K, Golden L, Burke L
Division of Epidemiology and Surveillance, Food and Drug Administration, Rockville, Maryland.
Obstet Gynecol. 1995 Jan;85(1):6-10. doi: 10.1016/0029-7844(94)00339-f.
To describe trends in the prescription of menopausal estrogens and medroxyprogesterone in the United States.
Annual estimates of the number of prescriptions for menopausal estrogens and medroxyprogesterone and descriptive information on patients and providers were obtained from two pharmaceutical marketing research data bases, the National Prescription Audit and the National Disease and Therapeutic Index of IMS America.
An estimated 13.6 million prescriptions were dispensed for oral menopausal estrogens in 1982, and 31.7 million in 1992, a 2.3-fold increase (P = .0001). In 1992, Premarin, the only oral conjugated estrogen currently approved for use, was the most frequently dispensed brand-name pharmaceutical in the United States. Dispensed prescriptions for Estraderm, a transdermal estradiol first marketed in 1986, increased from 1.5 million in 1987 to 4.7 million in 1992. Dispensed prescriptions for oral medroxyprogesterone also increased from 2.3 million prescriptions in 1982 to 11.3 million in 1992, a 4.9-fold increase (P = .0001). An estimated one in six to one in four postmenopausal women were taking menopausal hormones in 1992. These drugs were prescribed mainly by obstetrician-gynecologists.
The use of menopausal estrogens and medroxyprogesterone has increased substantially over the past decade. These trends indicate that American women are widely exposed to menopausal hormone replacement.
描述美国绝经后雌激素和甲羟孕酮的处方趋势。
从两个药品营销研究数据库，即美国IMS公司的国家处方审计数据库和国家疾病与治疗指数数据库，获取绝经后雌激素和甲羟孕酮的年处方量估计值以及患者和医疗服务提供者的描述性信息。
1982年口服绝经后雌激素的处方量估计为1360万，1992年为3170万，增长了2.3倍（P = 0.0001）。1992年，目前唯一被批准使用的口服结合雌激素倍美力，是美国处方量最高的品牌药。1986年首次上市的经皮雌二醇制剂爱斯妥，其处方量从1987年的150万增加到1992年的470万。口服甲羟孕酮的处方量也从1982年的230万增加到1992年的1130万，增长了4.9倍（P = 0.0001）。1992年，估计每六到四名绝经后妇女中就有一人在服用绝经激素。这些药物主要由妇产科医生开具。
在过去十年中，绝经后雌激素和甲羟孕酮的使用大幅增加。这些趋势表明美国女性广泛接受绝经激素替代治疗。
